Hyperinflation and spirometry at week 6
| Treatment (n) | Adjusted mean (SE) | Change from baseline (95% CI) | Treatment difference (95% CI) | P value | |
| Lung hyperinflation | |||||
| FRC plethysmography (%) | T/O (59) | 146.783 (2.065) | –18.168 (–22.262 to –14.074) | –7.957 (–12.865 to –3.050) | 0.0019 |
| F/S (59) | 154.740 (2.066) | –10.211 (–14.308 to –6.113) | |||
| FRC (L) | T/O (59) | 4.770 (0.069) | –0.581 (–0.718 to –0.443) | –0.252 (–0.413 to –0.091) | 0.0028 |
| F/S (59) | 5.022 (0.069) | –0.329 (–0.466 to –0.191) | |||
| RVol (L) | T/O (58) | 3.742 (0.067) | –0.572 (–0.704 to –0.439) | –0.251 (–0.409 to –0.093) | 0.0024 |
| F/S (58) | 3.993 (0.067) | –0.321 (–0.453 to –0.188) | |||
| IC (L) | T/O (58) | 2.066 (0.061) | 0.320 (0.198 to 0.433) | 0.032 (–0.084 to 0.148) | 0.5832 |
| F/S (58) | 2.035 (0.061) | 0.289 (0.166 to 0.411) | |||
| TLC (L) | T/O (58) | 6.962 (0.071) | –0.206 (–0.347 to –0.066) | –0.184 (–0.358 to –0.010) | 0.0390 |
| F/S (58) | 7.146 (0.071) | –0.023 (–0.163 to 0.118) | |||
| Spirometry | |||||
| FEV1 (L) | T/O (59) | 1.725 (0.037) | 0.339 (0.266 to 0.412) | 0.180 (0.121 to 0.240) | <0.0001 |
| F/S (59) | 1.545 (0.037) | 0.158 (0.086 to 0.231) | |||
| FVC (L) | T/O (59) | 3.556 (0.054) | 0.445 (0.338 to 0.552) | 0.286 (0.171 to 0.400) | <0.0001 |
| F/S (59) | 3.270 (0.054) | 0.159 (0.052 to 0.266) |
FEV1, forced expiratory volume in 1 s; FRC, functional residual capacity; F/S, fluticasone propionate/salmeterol; FVC, forced vital capacity; IC, inspiratory capacity; RVol, residual lung volume; TLC, total lung capacity; T/O, tiotropium/olodaterol.